(Q45419512)

14 December 2017

title

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients (English)

1 reference

14 December 2017

1 reference

1 reference

Willy Rozenbaum

7

0 references

Pascale Trimoulet

3

object named as

Pascale Trimoulet

0 references

Christine Katlama

6

object named as

Christine Katlama

0 references

Gwénaël Le Teuff

8

object named as

Gwenael Le Teuff

1 reference

14 December 2017

Yves Benhamou

1

1 reference

14 December 2017

Herve Fleury

2

1 reference

14 December 2017

Isabelle Pellegrin

4

1 reference

14 December 2017

Renaud Urbinelli

5

1 reference

14 December 2017

Aldo Trylesinski

9

1 reference

14 December 2017

Christophe Piketty

10

1 reference

14 December 2017

TECOVIR Study Group

11

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

14 December 2017

1 reference

14 December 2017

volume

43

1 reference

14 December 2017

issue

3

1 reference

14 December 2017

page(s)

548-555

1 reference

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers

14 December 2017

cites work

1 reference

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

21 January 2018

1 reference

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

21 January 2018

1 reference

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

Hepatitis B: an important public health issue

21 January 2018

1 reference

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

7 January 2021

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort

1 reference

7 January 2021

Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment

1 reference

7 January 2021

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

1 reference

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

7 January 2021

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus

1 reference

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

7 January 2021

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

1 reference

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

7 January 2021

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

1 reference

7 January 2021

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

7 January 2021

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

1 reference

7 January 2021

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

7 January 2021

Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation

1 reference

7 January 2021

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

1 reference

7 January 2021

Tenofovir therapy for lamivudine resistance following liver transplantation

1 reference

7 January 2021

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

1 reference

7 January 2021

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

1 reference

7 January 2021

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

1 reference

7 January 2021

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

7 January 2021

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

1 reference

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

7 January 2021

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

1 reference

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21055

1 reference

14 December 2017

1 reference